{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Type+2+Diabetes+%28T2DM%29&page=4",
    "query": {
      "condition": "Type 2 Diabetes (T2DM)",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 241,
    "total_pages": 25,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Type+2+Diabetes+%28T2DM%29&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Type+2+Diabetes+%28T2DM%29&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T04:10:46.253Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02526524",
      "title": "Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Met DR",
          "type": "DRUG"
        },
        {
          "name": "Met IR",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elcelyx Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "25 Years and older"
      },
      "enrollment_count": 571,
      "start_date": "2015-09",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2018-04-27",
      "last_synced_at": "2026-10-07T04:10:46.253Z",
      "location_count": 134,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Tuscumbia, Alabama + 107 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tuscumbia",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02526524"
    },
    {
      "nct_id": "NCT01002547",
      "title": "Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Nonalcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "pioglitazone-placebo",
          "type": "DRUG"
        },
        {
          "name": "pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "Vitamin E",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Vitamin E-placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 105,
      "start_date": "2010-06-24",
      "completion_date": "2016-12-31",
      "has_results": true,
      "last_update_posted_date": "2018-09-11",
      "last_synced_at": "2026-10-07T04:10:46.253Z",
      "location_count": 2,
      "location_summary": "Gainesville, Florida • San Antonio, Texas",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01002547"
    },
    {
      "nct_id": "NCT05761301",
      "title": "A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus (T2DM)"
      ],
      "interventions": [
        {
          "name": "ALN-KHK",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 49,
      "start_date": "2023-03-10",
      "completion_date": "2025-04-03",
      "has_results": false,
      "last_update_posted_date": "2025-05-07",
      "last_synced_at": "2026-10-07T04:10:46.253Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • Vista, California • Lake Worth, Florida + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Vista",
          "state": "California"
        },
        {
          "city": "Lake Worth",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05761301"
    },
    {
      "nct_id": "NCT04083248",
      "title": "Building Self-regulation Capacity in AA T2DM Women: Feasibility of EMI",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Self-regulation"
      ],
      "interventions": [
        {
          "name": "Feasibility group",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "40 Years and older · Female only"
      },
      "enrollment_count": 11,
      "start_date": "2019-09-20",
      "completion_date": "2020-07-31",
      "has_results": false,
      "last_update_posted_date": "2021-05-03",
      "last_synced_at": "2026-10-07T04:10:46.253Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04083248"
    },
    {
      "nct_id": "NCT01525238",
      "title": "PK Study of Dapagliflozin in Pediatric Subjects With T2DM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 53,
      "start_date": "2012-07-01",
      "completion_date": "2014-09-01",
      "has_results": true,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-10-07T04:10:46.253Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01525238"
    },
    {
      "nct_id": "NCT02058160",
      "title": "Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Insulin glargine/lixisenatide (HOE901/AVE0010)",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine (HOE901)",
          "type": "DRUG"
        },
        {
          "name": "Metformin (Background Drug)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 736,
      "start_date": "2014-01",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2017-05-09",
      "last_synced_at": "2026-10-07T04:10:46.253Z",
      "location_count": 108,
      "location_summary": "Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 91 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02058160"
    },
    {
      "nct_id": "NCT02057172",
      "title": "Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "HM11260C",
          "type": "DRUG"
        },
        {
          "name": "liraglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hanmi Pharmaceutical Company Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 254,
      "start_date": "2014-01",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2016-08-09",
      "last_synced_at": "2026-10-07T04:10:46.253Z",
      "location_count": 1,
      "location_summary": "CA, California",
      "locations": [
        {
          "city": "CA",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02057172"
    },
    {
      "nct_id": "NCT00947557",
      "title": "Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type II"
      ],
      "interventions": [
        {
          "name": "Dutogliptin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 677,
      "start_date": "2009-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-09-21",
      "last_synced_at": "2026-10-07T04:10:46.253Z",
      "location_count": 98,
      "location_summary": "Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 84 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00947557"
    },
    {
      "nct_id": "NCT02113163",
      "title": "PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Non-Insulin-Dependent",
        "Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "Metformin Eicosapentaenoate",
          "type": "DRUG"
        },
        {
          "name": "Metformin HCl and Vascepa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Thetis Pharmaceuticals LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 32,
      "start_date": "2014-03",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2022-05-02",
      "last_synced_at": "2026-10-07T04:10:46.253Z",
      "location_count": 1,
      "location_summary": "Baton Rouge, Louisiana",
      "locations": [
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02113163"
    },
    {
      "nct_id": "NCT00817271",
      "title": "To Evaluate the Response to Glucagon During Hypoglycemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "AZD1656",
          "type": "DRUG"
        },
        {
          "name": "Glucagon",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 8,
      "start_date": "2009-02",
      "completion_date": "2009-04",
      "has_results": false,
      "last_update_posted_date": "2009-05-07",
      "last_synced_at": "2026-10-07T04:10:46.253Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00817271"
    }
  ]
}